- Home
- ESS vs INCY Comparison
ESS vs INCY Comparison
Compare ESS & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESS | INCY |
|---|---|---|
| Founded | 1971 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 17.0B |
| IPO Year | 1996 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ESS | INCY |
|---|---|---|
| Price | $243.90 | $94.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 21 |
| Target Price | ★ $282.30 | $102.00 |
| AVG Volume (30 Days) | 421.5K | ★ 1.4M |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | ★ 4.25% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | ★ 10.40 | 6.41 |
| Revenue | $1,887,345,000.00 | ★ $3,394,635,000.00 |
| Revenue This Year | $1.99 | $10.97 |
| Revenue Next Year | $3.39 | $10.48 |
| P/E Ratio | $23.27 | ★ $14.68 |
| Revenue Growth | 6.36 | ★ 13.67 |
| 52 Week Low | $238.46 | $53.56 |
| 52 Week High | $307.00 | $112.29 |
Technical Indicators
Market Signals| Indicator | ESS | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 49.04 |
| Support Level | N/A | $93.54 |
| Resistance Level | $263.53 | $108.79 |
| Average True Range (ATR) | 4.77 | 2.37 |
| MACD | -0.31 | 0.43 |
| Stochastic Oscillator | 29.77 | 80.89 |
Price Performance
Historical ComparisonAbout ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 259 apartment communities with over 63,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.